Clearside Overview Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially available in the U.S. Quarterly Summary Show all Latest Quarterly Results Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update Clearside Biomedical Q3 2022 Financial Results and OASIS Clinical Trial Data Call OASIS Phase 1/2a Clinical Trial Results Presentation 3.7 MB Form 10-Q View All News Releases Nov 22 2022 Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022 Nov 10 2022 Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference Nov 9 2022 Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update View All Events Piper Sandler 34th Annual Healthcare Conference Dec 1, 2022 at 9:50 AM EST Ophthalmology Innovation Summit (OIS) XII Dec 3, 2022 Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference Dec 8, 2022 at 2:45 PM EST View All Stock Quote Change Volume 52 Week High 52 Week Low Dec 1, 2022 6:30 AM EST Data Provided by Refinitiv. Minimum 15 minutes delayed.